title: Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement.
abstract: BACKGROUND
  In-stent restenosis is notoriously difficult to treat by repeat catheter intervention because of its propensity for aggressive recurrent neointimal formation. This study sought to assess the effectiveness and safety of the sirolimus-eluting stent in the treatment of in-stent restenosis.
  
  
  RESULTS
  The study was designed as a prospective multicenter registry. We included 162 patients with in-stent restenosis of a native coronary artery who had a clinical indication for repeat intervention. Patients were scheduled for follow-up angiography at 6 months. The primary end point was in-lesion late loss. Follow-up angiography was performed in 155 patients. We obtained an in-lesion late loss of 0.08+/-0.49 mm and a binary restenosis rate of 9.7% (15/155), which prompted reintervention in 7.4% (12/162) at 9 months. The 9-month rate of death was 1.2% (2/162) and that of nonfatal myocardial infarction was 1.2% (2/162).
  
  
  CONCLUSIONS
  Sirolimus-eluting stents were highly efficacious and safe in the treatment of in-stent restenosis. Our study provides rationale for the use of sirolimus-eluting stents in the treatment of in-stent restenosis.
authors.affiliation: Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany. franz-josef.neumann@herzzentrum.de
authors.forename: Franz-Josef
authors.initials: FJ
authors.lastname: Neumann
authors.forename: Walter
authors.initials: W
authors.lastname: Desmet
authors.forename: Eberhard
authors.initials: E
authors.lastname: Grube
authors.forename: Johannes
authors.initials: J
authors.lastname: Brachmann
authors.forename: Patrizia
authors.initials: P
authors.lastname: Presbitero
authors.forename: Paolo
authors.initials: P
authors.lastname: Rubartelli
authors.forename: Andreas
authors.initials: A
authors.lastname: Mügge
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Pede
authors.forename: Diana
authors.initials: D
authors.lastname: Füllgraf
authors.forename: Wim
authors.initials: W
authors.lastname: Aengevaeren
authors.forename: Leonardo
authors.initials: L
authors.lastname: Spedicato
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Popma
mesh_terms: D000368:Aged; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000401:mortality / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus